<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Letrozole: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Letrozole: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Letrozole: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10794" href="/d/html/10794.html" rel="external">see "Letrozole: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="94329" href="/d/html/94329.html" rel="external">see "Letrozole: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F187285"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Femara</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867337"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-Letrozole;</li>
<li>AG-Letrozole;</li>
<li>APO-Letrozole;</li>
<li>BIO-Letrozole;</li>
<li>CCP-Letrozole [DSC];</li>
<li>Femara;</li>
<li>JAMP-Letrozole;</li>
<li>Mar-Letrozole;</li>
<li>MINT-Letrozole;</li>
<li>NAT-Letrozole;</li>
<li>NRA-Letrozole;</li>
<li>PMS-Letrozole;</li>
<li>RAN-Letrozole [DSC];</li>
<li>RIVA-Letrozole;</li>
<li>SANDOZ Letrozole;</li>
<li>TEVA-Letrozole</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F187319"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Aromatase Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F187288"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f11018ba-205d-4754-ac29-da77a4af9d90">Breast cancer, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, adjuvant therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Early breast cancer, adjuvant treatment: </i>Postmenopausal patients: <b>Oral:</b> 2.5 mg once daily for a planned duration of 5 years; discontinue at relapse.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Early breast cancer, extended adjuvant treatment: </i>Postmenopausal patients: <b>Oral:</b> 2.5 mg once daily for a planned duration of 5 years (after 5 years of tamoxifen); discontinue at relapse. In clinical trials, letrozole was initiated within 3 months of discontinuing tamoxifen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14551341','lexi-content-ref-22042967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14551341','lexi-content-ref-22042967'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Early breast cancer, high-risk, adjuvant treatment in premenopausal patients (off-label use): </i>
<b>Oral:</b> 2.5 mg once daily (in combination with ovarian function suppression) for a duration of 5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31164265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31164265'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of adjuvant endocrine therapy:</i> American Society of Clinical Oncology (ASCO) guidelines for adjuvant endocrine therapy for women with hormone receptor<i>–</i>positive (HR+) breast cancer (focused update) recommend a duration of 5 to 10 years of adjuvant endocrine therapy; some patients may be appropriate candidates for extended aromatase inhibitor (AI) therapy for up to a total of 10 years based on disease recurrence risk and nodal disease status. Refer to the guidelines for specific recommendations based on menopausal status and tolerability (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30452337']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30452337'])">Ref</a></span>). Treatment with an additional 5 years of AI therapy (for a total of 10 years of endocrine therapy) demonstrated a significantly improved rate of disease-free survival and a decreased risk of disease recurrence and contralateral breast cancer (when compared to placebo); although, overall survival was not significantly different between groups, and bone-related adverse events occurred more frequently with letrozole versus placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27264120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27264120'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="acf71cbd-33d7-4a8f-a20f-f16dc2dbe205">Breast cancer, advanced, first- or second-line treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, advanced, first- or second-line treatment:</b> Postmenopausal patients: <b>Oral:</b> 2.5 mg once daily; continue until tumor progression.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bae109d8-7aa7-451f-9962-030bab8131fb">Breast cancer off-label combinations</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer off-label combinations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Breast cancer, advanced, estrogen receptor-positive, HER2-negative, first-line treatment:</b> Postmenopausal patients: <b>Oral:</b> 2.5 mg once daily (in combination with palbociclib) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27959613']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27959613'])">Ref</a></span>) <b>or</b> 2.5 mg once daily (in combination with ribociclib) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34414532','lexi-content-ref-27717303','lexi-content-ref-29718092','lexi-content-ref-31166679','lexi-content-ref-29804902']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34414532','lexi-content-ref-27717303','lexi-content-ref-29718092','lexi-content-ref-31166679','lexi-content-ref-29804902'])">Ref</a></span>) <b>or</b> 2.5 mg once daily (in combination with abemaciclib) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28968163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28968163'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Breast cancer, metastatic, hormone receptor–positive, HER2-positive:</b> Postmenopausal patients: <b>Oral:</b> 2.5 mg once daily (in combination with lapatinib) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19786658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19786658'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Breast cancer, metastatic, hormone receptor–positive, HER2-positive, salvage therapy:</b> Postmenopausal patients: <b>Oral:</b> 2.5 mg once daily (in combination with trastuzumab and lapatinib) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32822287']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32822287'])">Ref</a></span>). <b>Note:</b> Patients in the study had received prior endocrine therapy and had disease progression during or after a prior regimen containing trastuzumab plus chemotherapy in the neo(adjuvant) setting and/or first-line metastatic setting.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef12445f-5450-4468-80d0-329501655968">Breast cancer in male patients, hormone receptor–positive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer in male patients, hormone receptor–positive (off-label use): Note: </b>Should be used in combination with a gonadotropin-releasing hormone agonist/antagonist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuva</i>
<i>nt therapy (alternative agent):</i> May be used as adjuvant therapy in male patients with hormone receptor<i>–</i>positive (HR+) breast cancer with a contraindication to tamoxifen. ASCO guidelines for management of male breast cancer recommend an initial duration of 5 years of adjuvant endocrine therapy; if there still is a high risk of recurrence, 5 additional years of endocrine therapy may be offered if the initial 5 years of adjuvant therapy have been completed and tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Advanced or metastatic disease:</i>
<b>Oral:</b> 2.5 mg once daily until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23722469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23722469'])">Ref</a></span>). Endocrine therapy for males with advanced or metastatic, HR+, HER2-negative breast cancer may be sequenced as in females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058842']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058842'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c65159b6-3877-4146-9061-ba86fc309105">Infertility/Ovulation stimulation in anovulatory patients with polycystic ovary syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Infertility/Ovulation stimulation in anovulatory patients with polycystic ovary syndrome (off-label use):</b> Initial dose: <b>Oral:</b> 2.5 mg once daily for 5 days, starting on day 3, 4, or 5 following menses or progestin induced bleed; may increase to 5 mg/day for 5 days in subsequent cycles if ovulation does not occur. Maximum dose: 7.5 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29794677','lexi-content-ref-25006718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29794677','lexi-content-ref-25006718'])">Ref</a></span>). Dosing for up to 5 cycles was used in 1 study (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25006718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25006718'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="78ed2fe2-7ca4-482a-9c6b-d4cfbd62290c">Ovarian cancer, epithelial, recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, epithelial, recurrent (off-label use):</b>
<b>Oral:</b> 2.5 mg once daily; continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18457865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18457865'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991778"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed (lipophilic and relatively large V<sub>d</sub>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24158084','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24158084','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (lipophilic and relatively large V<sub>d</sub>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988935"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C) and cirrhosis: 2.5 mg every other day</p>
<p style="text-indent:-2em;margin-left:2em;">Noncirrhotic patients with elevated bilirubin: There are no dosage adjustments provided in the manufacturer's labeling (effect has not been determined).</p></div>
<div class="block dot drugH1Div" id="F56556732"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Hyperlipidemia: May require antihyperlipidemic medication.</p></div>
<div class="block doe drugH1Div" id="F187289"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F52812527"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="94329" href="/d/html/94329.html" rel="external">see "Letrozole: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7471abe8-bd58-44ac-b865-e47b18736eb5">Constitutional delay of growth and puberty</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Constitutional delay of growth and puberty (CDGP):</b> Limited data available: Male Adolescents ≥14 years: Oral: 2.5 mg once daily with or without testosterone therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22296078','lexi-content-ref-30612946','lexi-content-ref-11403810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22296078','lexi-content-ref-30612946','lexi-content-ref-11403810'])">Ref</a></span>). A phase 3 randomized comparative controlled trial in adolescent males (n= 30; mean age: ~15 years; testosterone group n=15; letrozole n=15) reported subjects treated with letrozole showed higher levels of the puberty markers LH, FSH, testosterone, and inhibin B and significantly greater testicular growth compared to the testosterone treatment group (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30612946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30612946'])">Ref</a></span>). When used in combination with testosterone, bone maturation was delayed, predicted adult height values were significantly increased, and markers of puberty progressed during the 12 months of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22296078','lexi-content-ref-11403810']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22296078','lexi-content-ref-11403810'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c699c19b-0114-416d-b89f-9805c09eb18a">McCune-Albright syndrome; precocious puberty</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>McCune-Albright syndrome; precocious puberty:</b> Very limited data available: Female Children &gt;2 to 8 years at time of treatment initiation: Oral: Initial: 0.5 mg/m<sup>2</sup>/day in divided doses every 12 hours for days 1 to 7, then 1 mg/m<sup>2</sup>/day in divided doses every 12 hours on days 8 to 14, then 1.5 mg/m<sup>2</sup>/day in divided doses every 12 hours beginning on day 15; if needed, may further increase to 2 mg/m<sup>2</sup>/day in divided doses if markers of precocious puberty including serum estradiol levels continue to progress. Dosing based on a pilot study of nine girls (3 to 8 years at time of therapy initiation) which showed long-term therapy (up to 36 months) decreased rates of growth and bone maturation; although ovarian volume decreased during the first 6 months of treatment, the mean ovarian volume increased over 1 to 2 years of therapy with cyst redevelopment in some patients. During the pilot study, dosing was divided twice daily to alleviate GI discomfort; however, pharmacokinetic analysis showed once daily dosing would be appropriate for young children if tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17405850']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17405850'])">Ref</a></span>). In a case series (n=3, age range at treatment: 3 to 7 years), a fixed dose of 2.5 mg once daily was used for 5 to 19 months duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22051789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22051789'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ef147c6a-61d4-4313-acb1-d20eb064e423">Short stature; idiopathic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Short stature; idiopathic:</b> Limited data available: Male Children ≥9 years and Adolescents &lt;17 years: Oral: 2.5 mg once daily. Dosing based on experience in a double-blind, placebo-controlled trial of 30 males (treatment group: n=16; age range: 9 to 14 years) and a retrospective observation (n=24; age range: 9 to 16 years); the duration of letrozole therapy was up to 2 years (range: 4 to 24 months); bone maturation delay with increases in predicted adult height values were observed with treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16189252','lexi-content-ref-15813607','lexi-content-ref-18381525']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16189252','lexi-content-ref-15813607','lexi-content-ref-18381525'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729746"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, data suggests no dosage adjustment is required.</p></div>
<div class="block dohp drugH1Div" id="F52729747"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block arsc drugH1Div" id="F55707387"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone mineral density loss/increased fracture risk</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Letrozole is associated with a <b>decreased bone mineral density</b> (BMD); decreases (from baseline) in total hip and lumbar spine BMD have been reported. Letrozole has been linked to bone resorption in postmenopausal females, an increased risk of <b>osteoporosis</b> and <b>bone fracture </b>should be considered with administering treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12404296','lexi-content-ref-16822845','lexi-content-ref-22003243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12404296','lexi-content-ref-16822845','lexi-content-ref-22003243'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related; letrozole decreases plasma estrogen levels. Low levels of estrogen have been linked to bone resorption leading to decreased BMD, especially at the lumbar spine and hip. This results in increased risk of osteoporosis and fracture (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16822845','lexi-content-ref-22003243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16822845','lexi-content-ref-22003243'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; bone loss occurred during the first 2 years of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22003243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22003243'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Longer durations of aromatase inhibitors (&gt;3 years of therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21743022','lexi-content-ref-28922781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21743022','lexi-content-ref-28922781'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting known risk factors for BMD loss, osteoporosis, and fracture; includes preexisting osteopenia, age &gt;65 years, years since menopause, body mass index &lt;20 kg/m<sup>2</sup>, personal/family history, chronic glucocorticoid use &gt;6 months, prior fragility fracture history, low bone mineral density, rheumatoid arthritis, and smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15928804','lexi-content-ref-15542027','lexi-content-ref-15125788','lexi-content-ref-15268886','lexi-content-ref-15455194','lexi-content-ref-15175845','lexi-content-ref-11136882','lexi-content-ref-25992285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15928804','lexi-content-ref-15542027','lexi-content-ref-15125788','lexi-content-ref-15268886','lexi-content-ref-15455194','lexi-content-ref-15175845','lexi-content-ref-11136882','lexi-content-ref-25992285'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ischemic cardiovascular events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ischemic heart disease</b> has been reported, with an increased incidence of ischemic cardiovascular events in patients with preexisting ischemic heart disease. <b>Angina pectoris</b> and <b>acute myocardial infarction</b> (MI) have occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non–dose-related; idiosyncratic. Aromatase inhibitors (AI), such as letrozole, reduce the protective effects of estrogen, consequently leading to increases in vasoconstriction and atherosclerosis. Additionally, there is dysregulation of lipid metabolism and potential risk of hyperlipidemia. Together, these factors may increase the risk of cardiovascular disease (CVD) in patients receiving AI for breast cancer treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30297439','lexi-content-ref-10362825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30297439','lexi-content-ref-10362825'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; cardiac ischemia may occur at any time during treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27100398']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27100398'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting CVD (including ischemic heart disease) or risk factors associated with CVD. In a large SEER-Medicare cohort evaluating MI risk with adjuvant hormone therapy, several preexisting conditions were associated with MI including diabetes with complications, heart failure, prior MI, coronary artery disease, and peripheral vascular disease. In patients with prior history of MI, hazard ratio was nearly 3-fold higher (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30443921']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30443921'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Longer durations of AI therapy (&gt;3 years of therapy) are associated with 18% to 26% increased risk of CVD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21743022','lexi-content-ref-30452337','lexi-content-ref-28922781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21743022','lexi-content-ref-30452337','lexi-content-ref-28922781'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Musculoskeletal effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Musculoskeletal effects (including new onset or exacerbation of existing <b>arthralgia</b>, joint stiffness, and/or <b>ostealgia</b>) may occur with letrozole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17761973','lexi-content-ref-17922185','lexi-content-ref-18021478','lexi-content-ref-16382061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17761973','lexi-content-ref-17922185','lexi-content-ref-18021478','lexi-content-ref-16382061'])">Ref</a></span>). Aromatase inhibitor-induced arthralgia presents with symmetrical joint pains most commonly affecting hands, wrists, and knees (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17761973']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17761973'])">Ref</a></span>). <b>Tenosynovitis </b>(trigger finger) and <b>carpal tunnel syndrome</b> may also be common complaints (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23471104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23471104'])">Ref</a></span>). These adverse reactions may significantly affect quality of life and the risk of treatment nonadherence or discontinuation should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27217455','lexi-content-ref-24355487','lexi-content-ref-26556210']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27217455','lexi-content-ref-24355487','lexi-content-ref-26556210'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; idiosyncratic. Exact mechanism is unknown; however, multiple mechanisms have been proposed involving estrogen depletion either as a direct or indirect cause. Proposed estrogen depletion mechanisms include direct local effects on joint tissues, increased inflammatory parameters, such as IL-6 indirectly affecting central and peripheral nociception (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16575867']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16575867'])">Ref</a></span>), decreased estradiol leading to a decrease in endogenous opioid levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16723535']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16723535'])">Ref</a></span>), collagen degradation, and impaired regulation of cartilage structure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21457526']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21457526'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; the median time to onset of symptoms is 1.6 months with a range of 0.4 to 10 months. Symptoms have been shown to peak ~6 months after initiation of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17922185']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17922185'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior menopausal hormone therapy and previous chemotherapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22265698','lexi-content-ref-18703382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22265698','lexi-content-ref-18703382'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Certain CYP19A1 single nucleotide polymorphisms (SNPs) have been associated with increased arthralgia symptoms and/or association with discontinuation of therapy due to intolerable arthralgia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32632513']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32632513'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F187255"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (7% to 18%), flushing (50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (24%), night sweats (15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (19% to 34%), hypercholesterolemia (52%), weight gain (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (9% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (3% to 14%), fatigue (10% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (≤25%)<span class="lexi-table-link-container"> (<a aria-label="Letrozole: Adverse Reaction: Arthralgia table link" class="lexi-table-link" data-table-id="lexi-content-letrozole-adverse-reaction-arthralgia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-letrozole-adverse-reaction-arthralgia')">table 1</a>)</span><span class="table-link" style="display:none;">Letrozole: Adverse Reaction: Arthralgia</span>, arthritis (≤25%)<span class="lexi-table-link-container"> (<a aria-label="Letrozole: Adverse Reaction: Arthritis table link" class="lexi-table-link" data-table-id="lexi-content-letrozole-adverse-reaction-arthritis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-letrozole-adverse-reaction-arthritis')">table 2</a>)</span><span class="table-link" style="display:none;">Letrozole: Adverse Reaction: Arthritis</span>, asthenia (6% to 34%)<span class="lexi-table-link-container"> (<a aria-label="Letrozole: Adverse Reaction: Asthenia table link" class="lexi-table-link" data-table-id="lexi-content-letrozole-adverse-reaction-asthenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-letrozole-adverse-reaction-asthenia')">table 3</a>)</span><span class="table-link" style="display:none;">Letrozole: Adverse Reaction: Asthenia</span>, back pain (5% to 18%), bone fracture (10% to 15%), ostealgia (5% to 22%)<span class="lexi-table-link-container"> (<a aria-label="Letrozole: Adverse Reaction: Ostealgia table link" class="lexi-table-link" data-table-id="lexi-content-letrozole-adverse-reaction-ostealgia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-letrozole-adverse-reaction-ostealgia')">table 4</a>)</span><span class="table-link" style="display:none;">Letrozole: Adverse Reaction: Ostealgia</span>, osteoporosis (5% to 15%)<span class="lexi-table-link-container"> (<a aria-label="Letrozole: Adverse Reaction: Osteoporosis table link" class="lexi-table-link" data-table-id="lexi-content-letrozole-adverse-reaction-osteoporosis" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-letrozole-adverse-reaction-osteoporosis')">table 5</a>)</span><span class="table-link" style="display:none;">Letrozole: Adverse Reaction: Osteoporosis</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Letrozole: Adverse Reaction: Arthralgia" frame="border" id="lexi-content-letrozole-adverse-reaction-arthralgia" rules="all">
<caption style="text-align:center;">
<b>Letrozole: Adverse Reaction: Arthralgia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,448</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,447</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Comparator: Tamoxifen; described as "arthralgia/arthritis"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">18%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,563</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,573</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">16%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">First-line treatment of advanced breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">455</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">455</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Comparator: Tamoxifen</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Letrozole: Adverse Reaction: Arthritis" frame="border" id="lexi-content-letrozole-adverse-reaction-arthritis" rules="all">
<caption style="text-align:center;">
<b>Letrozole: Adverse Reaction: Arthritis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤25%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">≤21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,448</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,447</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Comparator: Tamoxifen; described as "arthralgia/arthritis"</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,563</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,573</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Letrozole: Adverse Reaction: Asthenia" frame="border" id="lexi-content-letrozole-adverse-reaction-asthenia" rules="all">
<caption style="text-align:center;">
<b>Letrozole: Adverse Reaction: Asthenia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">34%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">32%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,563</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,573</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">First-line treatment of advanced breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">455</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">455</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Comparator: Tamoxifen</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Letrozole: Adverse Reaction: Ostealgia" frame="border" id="lexi-content-letrozole-adverse-reaction-ostealgia" rules="all">
<caption style="text-align:center;">
<b>Letrozole: Adverse Reaction: Ostealgia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,448</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,447</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Comparator: Tamoxifen</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">22%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">21%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">First-line treatment of advanced breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">455</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">455</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Comparator: Tamoxifen</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Letrozole: Adverse Reaction: Osteoporosis" frame="border" id="lexi-content-letrozole-adverse-reaction-osteoporosis" rules="all">
<caption style="text-align:center;">
<b>Letrozole: Adverse Reaction: Osteoporosis</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">15%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">12%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,448</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,447</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Comparator: Tamoxifen</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (13%), dyspnea (6% to 18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (1% to 2%)<span class="lexi-table-link-container"> (<a aria-label="Letrozole: Adverse Reaction: Acute Myocardial Infarction table link" class="lexi-table-link" data-table-id="lexi-content-letrozole-adverse-reaction-acute-myocardial-infarction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-letrozole-adverse-reaction-acute-myocardial-infarction')">table 6</a>)</span><span class="table-link" style="display:none;">Letrozole: Adverse Reaction: Acute Myocardial Infarction</span>, angina pectoris (1%)<span class="lexi-table-link-container"> (<a aria-label="Letrozole: Adverse Reaction: Angina Pectoris table link" class="lexi-table-link" data-table-id="lexi-content-letrozole-adverse-reaction-angina-pectoris" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-letrozole-adverse-reaction-angina-pectoris')">table 7</a>)</span><span class="table-link" style="display:none;">Letrozole: Adverse Reaction: Angina Pectoris</span>, cardiac failure (1% to 2%), cerebrovascular accident (≤3%), chest pain (6% to 8%), chest wall pain (6%), hemorrhagic stroke (≤2%), hypertension (6% to 8%), peripheral edema (5%), thromboembolism (≤3%; including portal vein thrombosis, pulmonary embolism, thrombophlebitis, venous thrombosis), thrombotic stroke (≤2%), transient ischemic attacks (≤3%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Letrozole: Adverse Reaction: Acute Myocardial Infarction" frame="border" id="lexi-content-letrozole-adverse-reaction-acute-myocardial-infarction" rules="all">
<caption style="text-align:center;">
<b>Letrozole: Adverse Reaction: Acute Myocardial Infarction</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,448</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,447</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">At median follow-up of 96 months; comparator: Tamoxifen</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,448</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,447</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">At median treatment duration of 60 months; comparator: Tamoxifen</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Letrozole: Adverse Reaction: Angina Pectoris" frame="border" id="lexi-content-letrozole-adverse-reaction-angina-pectoris" rules="all">
<caption style="text-align:center;">
<b>Letrozole: Adverse Reaction: Angina Pectoris</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,448</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,447</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Angina pectoris requiring surgery; at median follow-up of 96 months; comparator: Tamoxifen</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,448</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,447</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Angina pectoris requiring surgery; at median treatment duration of 60 months; comparator: Tamoxifen</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight loss (6% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (≤4%), constipation (2% to 10%), diarrhea (8%), vomiting (3% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Mastalgia (2% to 7%), urinary tract infection (6%), vaginal hemorrhage (5%), vaginal irritation (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphedema (7%; post-mastectomy), second primary malignant neoplasm (2% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (7%), influenza (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression (5%), headache (4% to 8%), hemiparesis (≤2%), insomnia (6% to 7%), lethargy (&lt;10%), malaise (&lt;10%), pain (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain (4% to 10%), myalgia (7% to 9%)<span class="lexi-table-link-container"> (<a aria-label="Letrozole: Adverse Reaction: Myalgia table link" class="lexi-table-link" data-table-id="lexi-content-letrozole-adverse-reaction-myalgia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-letrozole-adverse-reaction-myalgia')">table 8</a>)</span><span class="table-link" style="display:none;">Letrozole: Adverse Reaction: Myalgia</span>, osteopenia (4%)<span class="lexi-table-link-container"> (<a aria-label="Letrozole: Adverse Reaction: Osteopenia table link" class="lexi-table-link" data-table-id="lexi-content-letrozole-adverse-reaction-osteopenia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-letrozole-adverse-reaction-osteopenia')">table 9</a>)</span><span class="table-link" style="display:none;">Letrozole: Adverse Reaction: Osteopenia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Letrozole: Adverse Reaction: Myalgia" frame="border" id="lexi-content-letrozole-adverse-reaction-myalgia" rules="all">
<caption style="text-align:center;">
<b>Letrozole: Adverse Reaction: Myalgia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,448</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,447</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Comparator: Tamoxifen</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,563</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,573</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Letrozole: Adverse Reaction: Osteopenia" frame="border" id="lexi-content-letrozole-adverse-reaction-osteopenia" rules="all">
<caption style="text-align:center;">
<b>Letrozole: Adverse Reaction: Osteopenia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,448</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,447</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Comparator: Tamoxifen</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal disease (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Ischemic heart disease<span class="lexi-table-link-container"> (<a aria-label="Letrozole: Adverse Reaction: Ischemic Heart Disease table link" class="lexi-table-link" data-table-id="lexi-content-letrozole-adverse-reaction-ischemic-heart-disease" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-letrozole-adverse-reaction-ischemic-heart-disease')">table 10</a>)</span><span class="table-link" style="display:none;">Letrozole: Adverse Reaction: Ischemic Heart Disease</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Letrozole: Adverse Reaction: Ischemic Heart Disease" frame="border" id="lexi-content-letrozole-adverse-reaction-ischemic-heart-disease" rules="all">
<caption style="text-align:center;">
<b>Letrozole: Adverse Reaction: Ischemic Heart Disease</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Letrozole)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Comparator)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adjuvant treatment of early breast cancer</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,448</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2,447</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Comparator: Tamoxifen</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Ovarian cyst</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Endometrial hyperplasia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Endometrial carcinoma, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arterial thrombosis, hypersensitivity angiitis (Kim 2020), palpitations, prolonged QT interval on ECG (Grouthier 2018), tachycardia, ventricular arrhythmia (Grouthier 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, erythema nodosum (Kim 2020), skin rash (Finn 2016), toxic epidermal necrolysis (Chia 2006), urticaria, xeroderma (Finn 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased thirst</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (Finn 2016), dysgeusia (Finn 2016), dyspepsia (Finn 2016), increased appetite, stomatitis (Finn 2016), xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency, vaginal discharge</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (Finn 2016), leukopenia (Finn 2016), neutropenia (Finn 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (Finn 2016), carpal tunnel syndrome (Niravath 2013), dysesthesia, irritability (Goodwin 2006), memory impairment, nervousness, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Decreased bone mineral density (Perez 2006), subacute cutaneous lupus erythematosus (Kim 2020), tenosynovitis (trigger finger) (Niravath 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, dry eye syndrome (Turaka 2013), eye irritation</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (Finn 2016)</p></div>
<div class="block coi drugH1Div" id="F187268"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity to letrozole or any component of the formulation; pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to other aromatase inhibitors; use in patients &lt;18 years of age; premenopausal patients; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F187252"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause dizziness, fatigue, and somnolence; patients should be cautioned before performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased cholesterol: May increase total serum cholesterol. In patients treated with adjuvant therapy and cholesterol levels within normal limits, an increase of ≥1.5 x ULN in total cholesterol (nonfasting) has been demonstrated in 8.2% of letrozole-treated patients (25% requiring lipid-lowering medications) versus 3.2% of tamoxifen-treated patients (16% requiring medications).</p></div>
<div class="block foc drugH1Div" id="F187263"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Femara: 2.5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg</p></div>
<div class="block geq drugH1Div" id="F187248"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F187270"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Femara Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $31.79</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Letrozole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $10.41 - $18.13</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867338"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Femara: 2.5 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg</p></div>
<div class="block adm drugH1Div" id="F6743706"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer without regard to meals.</p></div>
<div class="block admp drugH1Div" id="F52613135"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer without regard to meals.</p></div>
<div class="block hazard drugH1Div" id="F49104527"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F187264"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer in postmenopausal patients:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Adjuvant treatment of hormone receptor-positive early breast cancer.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended adjuvant treatment of early breast cancer after 5 years of adjuvant tamoxifen therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">First-line treatment of hormone receptor-positive, locally-advanced or metastatic breast cancer.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of advanced breast cancer in patients with disease progression following antiestrogen therapy.</p></div>
<div class="block off-label drugH1Div" id="F25473551"><span class="drugH1">Use: Off-Label: Adult</span><p>Breast cancer, high-risk, hormone receptor–positive, adjuvant endocrine therapy in premenopausal patients (in combination with ovarian function suppression); Breast cancer in male patients, hormone receptor–positive; Infertility/Ovulation stimulation in anovulatory patients with polycystic ovary syndrome; Ovarian (epithelial) cancer, recurrent</p></div>
<div class="block mst drugH1Div" id="F187326"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Femara may be confused with Famvir, femhrt, Provera</p>
<p style="text-indent:-2em;margin-left:4em;">Letrozole may be confused with anastrozole</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Letaris, a formerly marketed Dutch brand name product for letrozole, may be confused with Letairis, a US brand name for ambrisentan.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F187313"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2A6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F187257"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: Aromatase Inhibitors may increase the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Aromatase Inhibitors may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nintedanib: Letrozole may increase the serum concentration of Nintedanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: May decrease the serum concentration of Letrozole.<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F51895354"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">A pregnancy test is recommended prior to starting letrozole therapy in all patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">When used for management of breast cancer, effective contraception should be used during letrozole therapy and for at least 3 weeks following the last letrozole dose.</p>
<p style="text-indent:0em;margin-top:2em;">Letrozole is used off-label for ovulation induction in patients with polycystic ovarian syndrome (PCOS) and anovulatory infertility when no other causes of infertility are present (ACOG 194 2018; Teede 2018). Baseline pregnancy testing is done prior to letrozole therapy to rule out unexpected ovulation, which prevents exposure in early pregnancy (Legro 2016). Because data related to newborn outcomes following maternal use are limited, guidelines recommend counseling patients of the off-label status prior to use (ACOG 194 2018).</p></div>
<div class="block pri drugH1Div" id="F187271"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in patients with an established pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Based on the mechanism of action and data from animal reproduction studies, letrozole may cause fetal harm if used during pregnancy.</p></div>
<div class="block brc drugH1Div" id="F20547807"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;">It is not known if letrozole is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for at least 3 weeks after the letrozole last dose.</p></div>
<div class="block dic drugH1Div" id="F187272"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Calcium and vitamin D supplementation are recommended.</p></div>
<div class="block mop drugH1Div" id="F187261"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Hormone receptor status. Hepatic function tests (at baseline); consider monitoring cholesterol panel and bone mineral density. Evaluate pregnancy status (prior to treatment in patients who could become pregnant). Monitor adherence.</p>
<p style="text-indent:-2em;margin-left:2em;">For infertility/ovarian stimulation (off-label use), a pregnancy test is recommended prior to initiation. Midluteal progestin concentrations (in a clinical study, nonresponse to treatment was defined as a progesterone concentration &lt;3 ng/mL during the midluteal phase; poor ovulatory response was defined as progesterone concentrations indicating ovulation but just above the cutoff point) (Legro 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring for patients with breast cancer: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking; estimate 10-year cardiovascular disease risk in patients without cardiovascular disease at baseline; assess cardiovascular risk annually in patients with a high 10-year risk (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F187251"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system which binds to the heme group of aromatase, a cytochrome P450 enzyme which catalyzes conversion of androgens to estrogens (specifically, androstenedione to estrone and testosterone to estradiol). This leads to inhibition of the enzyme and a significant reduction in plasma estrogen (estrone, estradiol and estrone sulfate) levels. Letrozole does not appear to affect synthesis of adrenal or thyroid hormones, aldosterone, or androgens.</p></div>
<div class="block phk drugH1Div" id="F187267"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Rapid and well absorbed; not affected by food</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~1.9 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding, plasma: Weak</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 and 2A6 to an inactive carbinol metabolite</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: ~2 days</p>
<p style="text-indent:-2em;margin-left:2em;">Time to steady state, plasma: 2 to 6 weeks; steady state serum concentrations are 1.5 to 2 times higher than single-dose values. In girls 3 to 9 years, steady state concentrations were 25% to 67% that of the mean adult values (Feuillan 2007)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~90%; 6% as unchanged drug, 75% as glucuronide carbinol metabolite, 9% as unidentified metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51198314"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: AUC was 37% higher in patients with mild to moderate hepatic impairment (Child-Pugh class A and B). AUC was increased 2-fold and systemic clearance was reduced 47% in patients with severe hepatic impairment (Child-Pugh class C).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F187273"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Cinfaletro | Femara | Letara | Letrozole denk | Rozlet</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cendalon | Cravetol | Fada letrozol | Femara | Idelara | Ingelet | Letrofarm gp pharm | Letrozol Biotenk | Letrozol eczane | Letrozol gen med | Letrozol glenmark | Letrozol hlb | Letrozol microsules | Letrozol varifarma | Trotech | Veuen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrofam | Letrozol +pharma | Letrozol accord | Letrozol actavis | Letrozol Arcana | Letrozol Bluefish | Letrozol G.L. | Letrozol Genericon | Letrozol Kabi | Letrozol Medico Uno | Letrozol Ratiopharm | Letrozol Sandoz | Letrozol stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo letrozole | Chemmart letrozole | Femara | Femolet | Fera | Gynotril | Letara | Letroz | Letrozole actavis | Letrozole an | Letrozole drla | Letrozole fbm | Letrozole ga | Letrozole gh | Letrozole rbx | Letrozole sandoz | Letrozole synthon | Lezole | Pharmacor letrozole | Pharmacy choice letrozole | Stada letrozole | Terry white chemists letrozole</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Femara | Femzole | Fezol | Lenor | Letrogen | Ovazol | Zoleta</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrozarom | Letrozol actavis | Letrozole accord | Letrozole apotex | Letrozole EG | Letrozole Mylan | Letrozole sandoz | Letrozole teva</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Letero</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Clarzole | Femara | Letrocon | Letrofemin | Letrogratis | Letrozol Nucleus | Letrozole alvogen | Letrozole neopharma | Letrozole winthrop | Lortanda | Zequipra</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Breelet | Femara | Ivevi | Lefemi | Lemol | Letrozol | Letrozol bergamo/amgen | Letrozol blau | Liliya | Noazy | Sabine | Soletre</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrozol actavis | Letrozol devatis | Letrozol helvepharm | Letrozol labatec | Letrozol Mylan | Letrozol orion | Letrozol Sandoz | Letrozol teva | Letrozol Zentiva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Letero | Ranmast</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrovitae | Letrozol | Losiral | Tiadis</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Femara | Fu rui | Letrozol</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Creatinon | Femara | Femgard | Gesamaf | Hb oncobreast | Latoren | Let | Letara | Letmam | Letoval | Letro seven | Letrocare | Letrole | Letroz | Letrozol | Lezoria</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Aletro | Apo letrozol | Arofek | Brenea | Dracenax | Etruzil | Femara | Lerana | Lestara | Letmylan | Letromedac | Letrovena | Letrozol +pharma | Letrozol apotex | Letrozol Mylan | Letrozol Ratiopharm | Letrozol stada | Letrozol teva | Letrozole Medico Uno | Letrozole Pharmacenter | Likarda | Ninivet | Oncozol | Trozara | Trozel</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Femar | Femara | Letro cell | Letroarom | Letroblock | Letrohexal | Letromedac | Letrozol 1 A Pharma | Letrozol 1a pharma | Letrozol AbZ | Letrozol accord | Letrozol actavis | Letrozol AL | Letrozol Aristo | Letrozol Axios | Letrozol Beta | Letrozol Biomo | Letrozol Bluefish | Letrozol CT | Letrozol denk | Letrozol devatis | Letrozol Dura | Letrozol Fair Med Healthcare | Letrozol glenmark | Letrozol Haemato | Letrozol hetero | Letrozol Heumann | Letrozol Hormosan | Letrozol Kabi | Letrozol onkovis | Letrozol Pfizer | Letrozol puren | Letrozol Q | Letrozol Ratiopharm | Letrozol stada | Letrozol sun | Letrozol Tecnimede | Letrozol Winthrop</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Losiral | Lupriza | Trozet</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Antif | Femara | Losiral | Lupriza</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrozol Ratiopharm | Letrozole accord | Letrozole Genericon | Letrozole polpharma | Letrozole Swiss | Letrozole teva | Lortanda</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Femapent | Femara | Letrotume</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Devazol | Femara | Galdar | Letrozol accord | Letrozol actavis | Letrozol Almus | Letrozol alter | Letrozol apotex | Letrozol Bluefish | Letrozol Cinfamed | Letrozol Combix | Letrozol Kern pharma | Letrozol mabo | Letrozol Mylan | Letrozol Normon | Letrozol Pensa | Letrozol pensa pharma | Letrozol Ratiopharm | Letrozol Sandoz | Letrozol stada | Letrozol sun | Letrozol tarbis | Letrozol Tecnigen | Letrozol teva | Letrozol vir | Letrozol Winthrop | Loxifan | Zarax</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrozol denk | Mamazol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Femar | Letrolan | Letrozol accord | Letrozol actavis | Letrozol Arrow | Letrozol Mylan | Letrozol orifarm | Letrozol orion | Letrozol Ratiopharm | Letrozol teva | Letrozole bluefish | Letrozole sandoz | Letrozole Stada</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrozole accord healthcare | Letrozole almus | Letrozole alter | Letrozole Arrow | Letrozole biogaran | Letrozole bluefish | Letrozole cristers | Letrozole EG | Letrozole evolugen | Letrozole Isomed | Letrozole Mylan | Letrozole phr lab | Letrozole ranbaxy | Letrozole ratiopharm | Letrozole sandoz | Letrozole Sun | Letrozole teva | Letrozole Zentiva | Letrozole Zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrozole Arrow | Letrozole sandoz | Letrozole teva</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Aromed | Femara | Femazac | Leoncon | Letropen | Letrozin | Letrozole Specifar | Letrozole teva | Letrozole/generics | Letrozole/mylan | Levinox | Linol | Mimor | Ratroz | Religan | Stefaplex | Trezor | Viobrest</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrozol Farmoz</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Avomit | Femara | Lametta | Letrilan | Letrofar | Letrozol actavis | Letrozol Genera | Letrozol JGL | Letrozol Sandoz | Siletris</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Etruzil | Famos | Femara | Letromataz | Letronorm | Letrovena | Letrozol actavis | Letrozol Kabi | Letrozol phace | Letrozol Polpharma | Letrozol Ratiopharm | Letrozol Sandoz | Letrozole bluefish | Letrozole Medico Uno | Letrozole mediner | Letrozole Mylan | Letrozole Pharmacenter | Letrozole teva | Lexeroll | Lortanda | Ninivet | Picozone</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Aromara | Femaplex | Femara | Lebrest | Lezra | Trozet</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Eirfem | Femara | Letrozole actavis | Letrozole bluefish | Letrozole Mylan | Letrozole teva | Letzo</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Femara</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Anolet | Aromatin | Brelet | Caditraz | Ccq l | Celofem | Chemlet | Clomipure l | Culet | E ova l | Evatrol | Fabova | Femara | Fempro | Feofer | Fertolet | Fertroz | Foliripe | Folletro | Goodova l | Herhope | Herlet | Induz | Letall | Letero | Letisha | Letnine | Letov | Letoval | Letozis | Letpro | Letroact | Letrocyt | Letrofil | Letroher | Letrohope | Letrolife | Letromac | Letronat | Letrova | Letroz | Letsi | Letzol | Lutrozole | Lytrol | Mamazol | Momazol | Newova | Oncolet | Oneova | Oreta | Ova plus l | Samlet | Stimu Let | Stimucor | Stimufol | Stimulet | Trozet | Zolet | Zuvitroz</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Letromal</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Brestoral | Calantha | Femara | Gosuran | Letrix | Letrozolo | Letrozolo Actavis | Letrozolo AHCL | Letrozolo almus | Letrozolo alter | Letrozolo Crinos | Letrozolo Doc Generici | Letrozolo fidia | Letrozolo germed | Letrozolo Mylan | Letrozolo pensa | Letrozolo Sandoz | Letrozolo Sun | Letrozolo tecnigen | Letrozolo Teva | Letrozolo Zentiva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Estrodex | Etofem | Fempro | Lefftara</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrozole ffp | Letrozole sandoz</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Femara | Fempro | Glotraz | Intez | Letero | Letroday | Letrofem | Letrol | Letroz</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bretra | Esmara | Femara | Lenara | Letron | Pamellar | Parnuel | Peratra | Teva letrozole | Trozet</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Femara</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Apo letrozole | Emvia | Femaplex | Femara | Femazol | Lefftara | Letrozole Arrow | Letrozole biogaran | Letrozole bluefish | Trozet</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrozol Polpharma | Letrozol Ratiopharm | Letrozole accord | Letrozole sanoswiss | Letrozole teva | Likarda | Picozone</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrozole EG</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrozole Genericon | Letrozole ratiopharm | Letrozole sanoswiss | Letrozole teva | Likarda</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Femara | Femolet | Letrozole cooper | Letrozole zenith</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Asuletus | Bionontrol | Femara | Gesamaf | Leroz | Letrozol | Letz | Rajendra | Solestrasa in | Trodis | Zolstro</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Femara | Lebreta | Letara | Letero | Letronat | Trozet</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Drecan | Femara | Impregnil | Letrozole denk</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letroman | Letrozol | Letrozol accord | Letrozol actavis | Letrozol CF | Letrozol focus | Letrozol Mylan | Letrozol Sandoz | Letrozol sun | Letrozol teva</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Femar | Femara | Letrozol | Letrozol accord | Letrozol medical valley | Letrozol Mylan | Letrozol orifarm | Letrozole sandoz</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letara | Letraccord | Letrole | Letromyl</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Antif | Fecinole | Femara | Let | Letrovitae | Letrozol</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Celofem | Dracenax | Femara | Hentrozole | Letero | Letoripe | Letov | Letrostad | Letroz | Letvex | Lezra | Mamazol</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Adezol | Aqate | Aromek | Avegest | Bloozol | Breta | Cansa | Cellzol | Febres | Femaget | Femaplex | Femara | Femizole | Femol | Fempro | Fetrozole | Fimra | Hilet | Interoz | Latromina | Leep | Leerose | Letara | Letfer | Letocor | Letonko | Letorel | Letova | Letra | Letraben | Letramed | Letrasan | Letrazo | Letrodrx | Letrofold | Letrofoz | Letrolex | Letrowrd | Lets | Letson | Letz sure | Letzole | Lezra | Litrazon | Litrex | Livazole | Losiral | Mamozol | Medlee | Oreta | Osume | Senora | Shelet | Sliczole | Synlet | Tapestro | Troza | Trozet | Trozo | Trozol | U salet | Walzole | Wimzole | Zolara | Zolix | Zomed | Zor</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Apo Letro | Arogen | Aromek | Clarzole | Etruzil | Femara | Lametta | Letralan | Letromedac | Letrozol teva | Letrozole accord | Letrozole apotex | Letrozole bluefish | Letrozolum polpharma | Lortanda | Lostar | Mionic | Symletrol | Trozebax</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Femara</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrozol | Letrozol accord | Letrozol actavis | Letrozol alter | Letrozol Farmoz | Letrozol Generis | Letrozol Hikma | Letrozol Kabi | Letrozol Pharmakern | Letrozol Sandoz | Letrozol stada | Letrozol synthon | Letrozol Tecnimede | Letrozol teva | Letrozol Tolife</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Famara | Fecinole | Femara | Letroz | Letrozol bioteng | Letrozol gebina | Letrozol imedic | Letrozol intas | Letrozol microsules | Letrozol quimfa | Letrozol seven | Letrozol suntec | Letrozol tuteur | Letrozol varifarma | Losiral | Lupriza</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Femara</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Elozora | Etruzil | Femara | Letralan | Letrozol atb | Letrozol stada | Letrozol teva | Lezra | Lortanda | Trozel | Zequipra | Zotrol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Estrolet | Etruzil | Extraza | Femara | Lestrodex | Letrose | Letrosun | Letrotera | Letroza | Letrozol | Letrozole teva | Loreta | Nexazole | Oreta</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo letrozole | Femaplex | Femara | Lefftara | Letara | Pms letrozole | Rozlet</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Femar | Letrozol 2care4 | Letrozol abacus medicine | Letrozol accord | Letrozol actavis | Letrozol Arrow | Letrozol ebb | Letrozol medical valley | Letrozol Mylan | Letrozol orifarm | Letrozol orion | Letrozol stada | Letrozol teva | Letrozole bluefish | Letrozole sandoz</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letero | Letrozole sandoz</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Femara | Femtozone | Lenizol | Letrozol teva | Lotestrol | Picozone</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Aletro | Brenea | Clarzole | Etruzil | Femara | Letromyl | Letrovena | Letrozol +pharma | Letrozol Mylan | Letrozol Polpharma | Letrozol Ratiopharm | Letrozol Sandoz | Letrozol stada | Letrozol teva | Letrozole Medico Uno | Letrozole Pharmacenter | Lidiozol | Lortanda | Ninivet | Oralet | Trozel</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letero | Letov | Letrozole alvogen | Trozet</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Femaplex | Femara | Gynotril | Lefftara | Letrozole actavis | Letrozole neapolis</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letrasan | Letroks | Letrol | Letu</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Femara | Lenozole | Letara | Letero | Letramase | Letrozole alvogen | Trozet</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Aralet | Etruzil | Femara | Lesra | Letero | Letoripe | Letromara | Letrotera | Letrovista | Letrozol | Letrozole genepharm | Letrozole krka | Letrozole vista ac</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Chemlet | Letero | Letrozole denk</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Fecinole | Femara | Letrofarm | Letroz | Lupriza</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Letrozol</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord letrozole | Cipla letrozole | Femara | Femzole | Laradex | Letraz | Letrozole hetero | Trozolt</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Oncolet | Trozet</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Femara | Letero | Letrasan</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29794677">
<a name="29794677"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Gynecology. American College of Obstetricians and Gynecologists Practice Bulletin No. 194: polycystic ovary syndrome. <i>Obstet Gynecol</i>. 2018;131(6):e157-e171. doi: 10.1097/AOG.0000000000002656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/29794677/pubmed" id="29794677" target="_blank">29794677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21743022">
<a name="21743022"></a>Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. <i>J Natl Cancer Inst</i>. 2011;103(17):1299-1309. doi:10.1093/jnci/djr242<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/21743022/pubmed" id="21743022" target="_blank">21743022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27511809">
<a name="27511809"></a>Balen AH, Morley LC, Misso M, et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. <i>Hum Reprod Update.</i> 2016;22(6):687-708.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/27511809/pubmed" id="27511809" target="_blank">27511809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22051789">
<a name="22051789"></a>Bercaw-Pratt JL, Moorjani TP, Santos XM, Karaviti L, Dietrich JE. Diagnosis and management of precocious puberty in atypical presentations of McCune-Albright syndrome: a case series review. <i>J Pediatr Adolesc Gynecol</i>. 2012;25(1):e9-e13. doi:10.1016/j.jpag.2011.09.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/22051789/pubmed" id="22051789" target="_blank">22051789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32632513">
<a name="32632513"></a>Borrie AE, Rose FA, Choi YH, et al. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. <i>Breast Cancer Res Treat</i>. 2020;183(2):365-372. doi:10.1007/s10549-020-05777-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/32632513/pubmed" id="32632513" target="_blank">32632513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30452337">
<a name="30452337"></a>Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. <i>J Clin Oncol</i>. 2019;37(5):423-438. doi:10.1200/JCO.18.01160<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/30452337/pubmed" id="30452337" target="_blank">30452337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26884586">
<a name="26884586"></a>Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. <i>J Clin Oncol</i>. 2016;34(14):1689-1701. doi:10.1200/JCO.2015.65.9573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/26884586/pubmed" id="26884586" target="_blank">26884586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12404296">
<a name="12404296"></a>Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. <i>Cancer</i>. 2002;95(9):2006-2016. doi:10.1002/cncr.10908<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/12404296/pubmed" id="12404296" target="_blank">12404296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16455483">
<a name="16455483"></a>Chia WK, Lim YL, Greaves MW, Ang P. Toxic epidermal necrolysis in patient with breast cancer receiving letrozole. <i>Lancet Oncol</i>. 2006;7(2):184-185. doi:10.1016/S1470-2045(06)70581-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/16455483/pubmed" id="16455483" target="_blank">16455483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27217455">
<a name="27217455"></a>Chirgwin JH, Giobbie-Hurder A, Coates AS, et al. Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence. <i>J Clin Oncol</i>. 2016;34(21):2452-2459. doi:10.1200/JCO.2015.63.8619<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/27217455/pubmed" id="27217455" target="_blank">27217455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17200148">
<a name="17200148"></a>Coates AS, Keshaviah A, Thurlimann B, et al, “Five Years of Letrozole Compared With Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98,” <i>J Clin Oncol</i>, 2007, 25(5):486-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/17200148/pubmed" id="17200148" target="_blank">17200148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17761973">
<a name="17761973"></a>Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. <i>J Clin Oncol</i>. 2007;25(25):3877-3883. doi:10.1200/JCO.2007.10.7573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/17761973/pubmed" id="17761973" target="_blank">17761973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15928804">
<a name="15928804"></a>De Laet C, Kanis JA, Odén A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. <i>Osteoporos Int</i>. 2005;16(11):1330-1338. doi:10.1007/s00198-005-1863-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/15928804/pubmed" id="15928804" target="_blank">15928804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34414532">
<a name="34414532"></a>De Laurentiis M, Borstnar S, Campone M, et al. Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population. <i>Breast Cancer Res Treat</i>. 2021;189(3):689-699. doi:10.1007/s10549-021-06334-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/34414532/pubmed" id="34414532" target="_blank">34414532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35123662">
<a name="35123662"></a>Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.<i> Lancet Oncol</i>. 2022;23(3):382-392. doi:10.1016/S1470-2045(21)00758-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/35123662/pubmed" id="35123662" target="_blank">35123662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Kenar D. Jhaveri, MD; Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novartis.1">
<a name="Novartis.1"></a>Femara (letrozole) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Novartis.2">
<a name="Novartis.2"></a>Femara (letrozole) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17405850">
<a name="17405850"></a>Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT. Letrozole treatment of precocious puberty in girls with McCune-Albright syndrome: a pilot study. <i>J Clin Endocrinol Metab</i>. 2007;92:2100-2106.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/17405850/pubmed" id="17405850" target="_blank">17405850</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27959613">
<a name="27959613"></a>Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. <i>N Engl J Med</i>. 2016;375(20):1925-1936. doi:10.1056/NEJMoa1607303<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/27959613/pubmed" id="27959613" target="_blank">27959613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29797697">
<a name="29797697"></a>Franik S, Eltrop SM, Kremer JA, et al. Aromatase inhibitors (letrozole) for subfertile women with polycystic ovary syndrome. <i>Cochrane Database Syst Rev</i>. 2018;5:CD010287. doi: 10.1002/14651858.CD010287.pub3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/29797697/pubmed" id="29797697" target="_blank">29797697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21457526">
<a name="21457526"></a>Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. <i>Breast Cancer Res</i>. 2011;13(2):205. doi:10.1186/bcr2818<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/21457526/pubmed" id="21457526" target="_blank">21457526</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28968163">
<a name="28968163"></a>Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. <i>J Clin Oncol</i>. 2017;35(32):3638-3646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/28968163/pubmed" id="28968163" target="_blank">28968163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28922781">
<a name="28922781"></a>Goldvaser H, Barnes TA, Šeruga B, et al. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. <i>J Natl Cancer Inst</i>. 2018;110(1):10.1093/jnci/djx141. doi:10.1093/jnci/djx141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/28922781/pubmed" id="28922781" target="_blank">28922781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17042891">
<a name="17042891"></a>Goodwin GM. Aromatase inhibitors and bipolar mood disorder: a case report. <i>Bipolar Disord</i>. 2006;8(5 Pt 1):516-518. doi:10.1111/j.1399-5618.2006.00367.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/17042891/pubmed" id="17042891" target="_blank">17042891</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14551341">
<a name="14551341"></a>Goss PE, Ingle JN, Martino S, et al. A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. <i>N Engl J Med</i>. 2003;349(19):1793-1802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/14551341/pubmed" id="14551341" target="_blank">14551341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27264120">
<a name="27264120"></a>Goss PE, Ingle JN, Pritchard KI, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. <i>N Engl J Med</i>. 2016;375(3):209-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/27264120/pubmed" id="27264120" target="_blank">27264120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29720397">
<a name="29720397"></a>Grouthier V, Lebrun-Vignes B, Glazer AM, et al. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. <i>Heart</i>. 2018;104(22):1859-1863. doi:10.1136/heartjnl-2017-312934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/29720397/pubmed" id="29720397" target="_blank">29720397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24355487">
<a name="24355487"></a>Hadji P, Jackisch C, Bolten W, et al. COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adjuvant anastrozole therapy. <i>Ann Oncol</i>. 2014;25(2):372-377. doi:10.1093/annonc/mdt513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/24355487/pubmed" id="24355487" target="_blank">24355487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27100398">
<a name="27100398"></a>Haque R, Shi J, Schottinger JE, et al. Cardiovascular disease after aromatase inhibitor use. <i>JAMA Oncol</i>. 2016;2(12):1590-1597. doi:10.1001/jamaoncol.2016.0429<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/27100398/pubmed" id="27100398" target="_blank">27100398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32058842">
<a name="32058842"></a>Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(16):1849-1863. doi:10.1200/JCO.19.03120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/32058842/pubmed" id="32058842" target="_blank">32058842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17922185">
<a name="17922185"></a>Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. <i>Breast Cancer Res Treat</i>. 2008;111(2):365-372. doi:10.1007/s10549-007-9774-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/17922185/pubmed" id="17922185" target="_blank">17922185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16189252">
<a name="16189252"></a>Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. <i>J Clin Endocrinol Metab</i>. 2005;90:6396-6402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/16189252/pubmed" id="16189252" target="_blank">16189252</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27717303">
<a name="27717303"></a>Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer.<i> N Engl J Med</i>. 2016;375(18):1738-1748.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/27717303/pubmed" id="27717303" target="_blank">27717303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29718092">
<a name="29718092"></a>Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. <i>Ann Oncol</i>. 2018;29(7):1541-1547. doi:10.1093/annonc/mdy155<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/29718092/pubmed" id="29718092" target="_blank">29718092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29392438">
<a name="29392438"></a>Hu S, Yu Q, Wang Y, et al. Letrozole versus clomiphene citrate in polycystic ovary syndrome: a meta-analysis of randomized controlled trials. <i>Arch Gynecol Obstet</i>. 2018;297(5):1081-1088. doi: 10.1007/s00404-018-4688-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/29392438/pubmed" id="29392438" target="_blank">29392438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31166679">
<a name="31166679"></a>Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. <i>N Engl J Med</i>. 2019;381(4):307-316. doi:10.1056/NEJMoa1903765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/31166679/pubmed" id="31166679" target="_blank">31166679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22042967">
<a name="22042967"></a>Jin H, Tu D, Zhao N, et al. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. <i>J Clin Oncol</i>. 2012;30:718-721.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/22042967/pubmed" id="22042967" target="_blank">22042967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19786658">
<a name="19786658"></a>Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. <i>J Clin Oncol</i>. 2009;27(33):5538-5546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/19786658/pubmed" id="19786658" target="_blank">19786658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32822287">
<a name="32822287"></a>Johnston SRD, Hegg R, Im SA, et al. Phase III, randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-positive, hormone receptor-positive metastatic breast cancer: updated results of ALTERNATIVE. <i>J Clin Oncol</i>. 2021;39(1):79-89. doi:10.1200/JCO.20.01894<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/32822287/pubmed" id="32822287" target="_blank">32822287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30443921">
<a name="30443921"></a>Kamaraju S, Shi Y, Smith E, Nattinger AB, Laud P, Neuner J. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study. <i>Clin Cardiol</i>. 2019;42(1):93-100. doi:10.1002/clc.23114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/30443921/pubmed" id="30443921" target="_blank">30443921</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15455194">
<a name="15455194"></a>Kanis JA, Johansson H, Johnell O, et al. Alcohol intake as a risk factor for fracture. <i>Osteoporos Int</i>. 2005;16(7):737-742. doi:10.1007/s00198-004-1734-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/15455194/pubmed" id="15455194" target="_blank">15455194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15542027">
<a name="15542027"></a>Kanis JA, Johansson H, Oden A, et al. A family history of fracture and fracture risk: a meta-analysis. <i>Bone</i>. 2004;35(5):1029-1037. doi:10.1016/j.bone.2004.06.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/15542027/pubmed" id="15542027" target="_blank">15542027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15125788">
<a name="15125788"></a>Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. <i>J Bone Miner Res</i>. 2004;19(6):893-899. doi:10.1359/JBMR.040134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/15125788/pubmed" id="15125788" target="_blank">15125788</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15268886">
<a name="15268886"></a>Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. <i>Bone</i>. 2004;35(2):375-382. doi:10.1016/j.bone.2004.03.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/15268886/pubmed" id="15268886" target="_blank">15268886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15175845">
<a name="15175845"></a>Kanis JA, Johnell O, Oden A, et al. Smoking and fracture risk: a meta-analysis. <i>Osteoporos Int</i>. 2005;16(2):155-162. doi:10.1007/s00198-004-1640-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/15175845/pubmed" id="15175845" target="_blank">15175845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15813607">
<a name="15813607"></a>Karmazin A, Moore WV, Popovic J, Jacobson JD. The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function. <i>J Pediatr Endocrinol Metab</i>. 2005;18:285-293.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/15813607/pubmed" id="15813607" target="_blank">15813607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31965545">
<a name="31965545"></a>Kim YJ, Cohen PR. Anastrozole-induced dermatitis: report of a woman with an anastrozole-associated dermatosis and a review of aromatase inhibitor-related cutaneous adverse events. <i>Dermatol Ther (Heidelb)</i>. 2020;10(1):221-229. doi:10.1007/s13555-020-00353-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/31965545/pubmed" id="31965545" target="_blank">31965545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27866938">
<a name="27866938"></a>Legro RS. Ovulation induction in polycystic ovary syndrome: current options. <i>Best Pract Res Clin Obstet Gynaecol.</i> 2016;37:152-159. doi: 10.1016/j.bpobgyn.2016.08.001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/27866938/pubmed" id="27866938" target="_blank">27866938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25006718">
<a name="25006718"></a>Legro RS, Brzyski RG, Diamond MP, et al; NICHD Reproductive Medicine Network. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. <i>N Engl J Med</i>. 2014;371(2):119-29. doi: 10.1056/NEJMoa1313517.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/25006718/pubmed" id="25006718" target="_blank">25006718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26556210">
<a name="26556210"></a>Lombard JM, Zdenkowski N, Wells K, et al. Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options. <i>Support Care Cancer</i>. 2016;24(5):2139-2146. doi:10.1007/s00520-015-3001-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/26556210/pubmed" id="26556210" target="_blank">26556210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30297439">
<a name="30297439"></a>Matthews A, Stanway S, Farmer RE, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. <i>BMJ</i>. 2018;363:k3845. doi:10.1136/bmj.k3845<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/30297439/pubmed" id="30297439" target="_blank">30297439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10362825">
<a name="10362825"></a>Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. <i>N Engl J Med</i>. 1999;340(23):1801-1811. doi:10.1056/NEJM199906103402306<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/10362825/pubmed" id="10362825" target="_blank">10362825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22265698">
<a name="22265698"></a>Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ; IES Steering Committee. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. <i>Lancet Oncol</i>. 2012;13(4):420-432. doi:10.1016/S1470-2045(11)70328-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/22265698/pubmed" id="22265698" target="_blank">22265698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22431566">
<a name="22431566"></a>Misso ML, Wong JL, Teede HJ, et al. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. <i>Hum Reprod Update.</i> 2012;18(3):301-312.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/22431566/pubmed" id="22431566" target="_blank">22431566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23471104">
<a name="23471104"></a>Niravath P. Aromatase inhibitor-induced arthralgia: a review. <i>Ann Oncol</i>. 2013;24(6):1443-1449. doi:10.1093/annonc/mdt037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/23471104/pubmed" id="23471104" target="_blank">23471104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22296078">
<a name="22296078"></a>Palmert MR, Dunkel L. Clinical practice. Delayed puberty. <i>N Engl J Med</i>. 2012;366(5):443-453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/22296078/pubmed" id="22296078" target="_blank">22296078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16822845">
<a name="16822845"></a>Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. <i>J Clin Oncol</i>. 2006;24(22):3629-3635. doi:10.1200/JCO.2005.05.4882<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/16822845/pubmed" id="16822845" target="_blank">16822845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31164265">
<a name="31164265"></a>Perrone F, De Laurentiis M, De Placido S, et al. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. <i>Eur J Cancer</i>. 2019;118:178-186. doi:10.1016/j.ejca.2019.05.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/31164265/pubmed" id="31164265" target="_blank">31164265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24158084">
<a name="24158084"></a>Piacentini F, Omarini C, Barbieri E. Lapatinib and renal impairment: a case report. <i>Tumori</i>. 2013;99(3):e134-135. doi:10.1177/030089161309900334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/24158084/pubmed" id="24158084" target="_blank">24158084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18021478">
<a name="18021478"></a>Presant CA, Bosserman L, Young T, et al. Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. <i>Clin Breast Cancer</i>. 2007;7(10):775-778. doi:10.3816/CBC.2007.n.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/18021478/pubmed" id="18021478" target="_blank">18021478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18457865">
<a name="18457865"></a>Ramirez PT, Schmeler EM, Milam MR, et al, “Efficacy of Letrozole in the Treatment of Recurrent Platinum- and Taxane-Resistant High-Grade Cancer of the Ovary or Peritoneum,” <i>Gynecol Oncol</i>, 2008, 110(1):56-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/18457865/pubmed" id="18457865" target="_blank">18457865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16575867">
<a name="16575867"></a>Ranganathan P, Armamento-Villareal R. Aromatase inhibitors and osteoporosis: comment on the review by Felson and Cummings. <i>Arthritis Rheum</i>. 2006;54(4):1355-1356. doi:10.1002/art.21741<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/16575867/pubmed" id="16575867" target="_blank">16575867</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18703382">
<a name="18703382"></a>Sestak I, Cuzick J, Sapunar F, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. <i>Lancet Oncol</i>. 2008;9(9):866-872. doi:10.1016/S1470-2045(08)70182-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/18703382/pubmed" id="18703382" target="_blank">18703382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18381525">
<a name="18381525"></a>Shulman DI, Francis GL, Palmert MR, et al. Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. <i>Pediatrics</i>. 2008;121(4):e975-983.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/18381525/pubmed" id="18381525" target="_blank">18381525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16723535">
<a name="16723535"></a>Smith YR, Stohler CS, Nichols TE, Bueller JA, Koeppe RA, Zubieta JK. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. <i>J Neurosci</i>. 2006;26(21):5777-5785. doi:10.1523/JNEUROSCI.5223-05.2006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/16723535/pubmed" id="16723535" target="_blank">16723535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30033227">
<a name="30033227"></a>Teede HJ, Misso ML, Costello MF, et al; International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. <i>Fertil Steril</i>. 2018;110(3):364-379. doi: 10.1016/j.fertnstert.2018.05.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/30033227/pubmed" id="30033227" target="_blank">30033227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16382061">
<a name="16382061"></a>Thurlimann B, Keshaviah A, Coates AS, et al; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer [published correction appears in <i>N Engl J Med</i>. 2006;354(20):2200]. <i>N Engl J Med</i>. 2005;353(26):2747-2757. doi:10.1056/NEJMoa052258<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/16382061/pubmed" id="16382061" target="_blank">16382061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29804902">
<a name="29804902"></a>Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor positive, advanced breast cancer (MONALEESA-7): a randomized phase 3 trial. <i>Lancet Oncol</i>. 2018;19(7):904-915. doi:10.1016/S1470-2045(18)30292-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/29804902/pubmed" id="29804902" target="_blank">29804902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16650422">
<a name="16650422"></a>Tulandi T, Martin J, Al-Fadhli R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. <i>Fertil Steril</i>. 2006;85(6):1761-1765.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/16650422/pubmed" id="16650422" target="_blank">16650422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22957932">
<a name="22957932"></a>Turaka K, Nottage JM, Hammersmith KM, Nagra PK, Rapuano CJ. Dry eye syndrome in aromatase inhibitor users. <i>Clin Exp Ophthalmol</i>. 2013;41(3):239-243. doi:10.1111/j.1442-9071.2012.02865.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/22957932/pubmed" id="22957932" target="_blank">22957932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11136882">
<a name="11136882"></a>van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. <i>Rheumatology (Oxford)</i>. 2000;39(12):1383-1389. doi:10.1093/rheumatology/39.12.1383<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/11136882/pubmed" id="11136882" target="_blank">11136882</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30612946">
<a name="30612946"></a>Varimo T, Huopio H, Kariola L, et al. Letrozole versus testosterone for promotion of endogenous puberty in boys with constitutional delay of growth and puberty: a randomised controlled phase 3 trial. <i>Lancet Child Adolesc Health</i>. 2019;3(2):109-120. doi:10.1016/S2352-4642(18)30377-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/30612946/pubmed" id="30612946" target="_blank">30612946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25992285">
<a name="25992285"></a>Waning DL, Guise TA. Cancer-associated muscle weakness: What's bone got to do with it? <i>Bonekey Rep</i>. 2015;4:691. doi:10.1038/bonekey.2015.59<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/25992285/pubmed" id="25992285" target="_blank">25992285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11403810">
<a name="11403810"></a>Wickman S, Sipilä I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled. <i>Lancet</i>. 2001;357:1743-1748.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/11403810/pubmed" id="11403810" target="_blank">11403810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25850534">
<a name="25850534"></a>Zagouri F, Sergentanis TN, Azim HA Jr, et al. Aromatase inhibitors in male breast cancer: a pooled analysis. <i>Breast Cancer Res Treat</i>. 2015;151(1):141-147. doi:10.1007/s10549-015-3356-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/25850534/pubmed" id="25850534" target="_blank">25850534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23722469">
<a name="23722469"></a>Zagouri F, Sergentanis TN, Koutoulidis V, et al. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. <i>Br J Cancer.</i> 2013;108(11):2259-2263. doi:10.1038/bjc.2013.255<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/23722469/pubmed" id="23722469" target="_blank">23722469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22003243">
<a name="22003243"></a>Zaman K, Thürlimann B, Huober J, et al. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). <i>Ann Oncol</i>. 2012;23(6):1474-1481. doi:10.1093/annonc/mdr448<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/letrozole-drug-information/abstract-text/22003243/pubmed" id="22003243" target="_blank">22003243</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10064 Version 319.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
